EP. 10 Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
November 21st, 2026The OncFive: Top Oncology Articles for the Week of 11/15The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.Read more
November 20th, 2026Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDACDaraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.Read more
November 20th, 2026TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal AdenocarcinomaSac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.Read more
November 20th, 2026Zelma and William Reid Commit $10 million to Establish Program for Pancreatic Cancer Interception and Prevention A gift to MD Anderson Cancer Center supports innovative pancreatic cancer research.Read more
November 20th, 2026Experts Tackle Key Questions on MAPK-Directed Therapy, Frontline PARP Inhibitor Maintenance, and ADCs in Ovarian CancerGynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.Read more
November 20th, 2026OncLive Weekly News Quiz (11/20/2026): Did You Miss Crucial Lung Cancer, PCNSL, Gastroesophageal Cancer, and AML Updates?Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.Read more
November 19th, 2026Response-Based Dosing and Mutation Testing Guide Ponatinib Use in CMLJorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.Read more
November 19th, 2026EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical CancersThe EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.Read more